Imperial College-based biotech startup Baseimmune has secured $4.8m funding to develop the next generation of future-proof universal vaccines against existing and emerging human and animal health threats including COVID, malaria and African Swine Fever. The latest £3.5m investment round, led by Hoxton Ventures, will enable the company to grow, developing more vaccines in parallel and... Read more »

The post Baseimmune closes $4.8m funding round to future-proof vaccines appeared first on Lifescience Industry News.